tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders StocksMarket MoversTipRanks 50 IndexAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsTrump Dashboard
New
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Advertisement
Advertisement

IMMX Stock Latest News

Immix Biopharma price target raised to $8 from $7 at H.C. Wainwright
The FlyImmix Biopharma price target raised to $8 from $7 at H.C. Wainwright
8d ago
IMMX
Immix Biopharma appoints Nancy Chang to board of directors
PremiumThe Fly
Immix Biopharma appoints Nancy Chang to board of directors
9d ago
IMMX
Immix Biopharma Completes Private Placement Transaction
PremiumCompany Announcements
Immix Biopharma Completes Private Placement Transaction
12d ago
8K
IMMX
Immix Biopharma receives strategic investment from Goose Capital
PremiumThe Fly
Immix Biopharma receives strategic investment from Goose Capital
12d ago
IMMX
Immix Biopharma announces ‘class-leading’ safety profile for NXC-201
PremiumThe Fly
Immix Biopharma announces ‘class-leading’ safety profile for NXC-201
2M ago
IMMX
Immix Biopharma’s Strategic Expansion and Promising Trial Results Reinforce Buy Rating
PremiumRatingsImmix Biopharma’s Strategic Expansion and Promising Trial Results Reinforce Buy Rating
2M ago
IMMX
Immix Biopharma announces accelerated NEXICART-2 trial progress
Premium
The Fly
Immix Biopharma announces accelerated NEXICART-2 trial progress
3M ago
IMMX
Immix Biopharma Holds Annual Meeting, Elects Directors
Premium
Company Announcements
Immix Biopharma Holds Annual Meeting, Elects Directors
3M ago
8K
IMMX
Promising Interim Results from NEXICART-2 Trial Support Buy Rating for NXC-201
PremiumRatings
Promising Interim Results from NEXICART-2 Trial Support Buy Rating for NXC-201
4M ago
IMMX
Immix Biopharma files $13.45M common stock ATM offering
PremiumThe Fly
Immix Biopharma files $13.45M common stock ATM offering
4M ago
IMMX
Immix Biopharma Enters At The Market Offering Agreement
PremiumCompany Announcements
Immix Biopharma Enters At The Market Offering Agreement
4M ago
8K
IMMX
Immix Biopharma announces NXC-201 trial met primary endpoint
PremiumThe Fly
Immix Biopharma announces NXC-201 trial met primary endpoint
4M ago
IMMX
Immix Biopharma expands U.S. clinical sites for NEXICART-2 trial
PremiumThe FlyImmix Biopharma expands U.S. clinical sites for NEXICART-2 trial
4M ago
IMMX
Buy Rating for Immix Biopharma: Promising Clinical Advancements and Market Potential of NXC-201
Premium
Ratings
Buy Rating for Immix Biopharma: Promising Clinical Advancements and Market Potential of NXC-201
7M ago
IMMX
Immix Biopharma receives FDA RMAT designation for NCX-201 in r/r AL Amyloidosis
Premium
The Fly
Immix Biopharma receives FDA RMAT designation for NCX-201 in r/r AL Amyloidosis
7M ago
IMMX
Immix Biopharma accelerates enrollment in U.S. AL amyloidosis trial of NXC-201
PremiumThe Fly
Immix Biopharma accelerates enrollment in U.S. AL amyloidosis trial of NXC-201
9M ago
IMMX
Immix Biopharma announces data from four patients in NEXICART-2 U.S. trial
PremiumThe Fly
Immix Biopharma announces data from four patients in NEXICART-2 U.S. trial
9M ago
IMMX
Immix Biopharma announces publication of NXC-201 clinical results
PremiumThe Fly
Immix Biopharma announces publication of NXC-201 clinical results
9M ago
IMMX
Immix Biopharma reports 75% CRR for NXC-201 in r/r AL amyloidosis patients
PremiumThe Fly
Immix Biopharma reports 75% CRR for NXC-201 in r/r AL amyloidosis patients
9M ago
IMMX
Immix Biopharma: Ex-US study of NXC-201 produced 92% ORR in r/r AL Amyloidosis
PremiumThe FlyImmix Biopharma: Ex-US study of NXC-201 produced 92% ORR in r/r AL Amyloidosis
12M ago
IMMX
Immix Biopharma announces three more sites for NEXICART-2 trial
Premium
The Fly
Immix Biopharma announces three more sites for NEXICART-2 trial
1y ago
IMMX
Immix Biopharma awarded $8M CLIN2 grant
Premium
The Fly
Immix Biopharma awarded $8M CLIN2 grant
1y ago
IMMX

Trending

Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >